DMP12

DMP12 is an experimental **bioactive cationic lipid** developed as a synthetic small-molecule excipient and potential anticancer agent. Chemically, it is a quaternary ammonium lipid formed by conjugating 3-(3,4-dimethoxyphenyl)propanoic acid to a twin C12-chain cationic amine scaffold. In the published study provided, DMP12 was incorporated into monoolein cubosomes, where its positive charge was intended to enhance interaction and fusion with cancer-cell membranes while its dimethoxyphenyl pharmacophore contributed intrinsic bioactivity. DMP12 showed direct cytotoxicity at higher concentrations in some cancer cell lines and, when co-formulated with paclitaxel in cubosomes, enhanced cytotoxicity against a paclitaxel-resistant prostate cancer cell line. It appears to be a preclinical research-stage lipid drug conjugate rather than an approved therapeutic product, and no specific commercial developer or manufacturer is clearly identified from the provided source.

Other names

N-(2-(3-(3,4-dimethoxyphenyl) propanamido) ethyl)-N-dodecyl-N-methyldodecan-1-aminium iodide